Biogen

Syndicate content

MS Patients May Soon Benefit from a New Generation of Oral Drugs

Greystone Associates Assesses the Potential and Prospects for Pipeline Candidates Targeting Multiple Sclerosis and their Probable Impact on Existing
Treatments

Get the full story...

Emerging Targets and Therapeutic Approaches Driving Activity in Autoimmune Disease Therapeutics

New Analysis by Applied Data Research Examines Clinical Developments and Assesses Market Impact

Get the full story...